French pharmaceutical manufacturer Laboratoires Fournier of Dijon has finalized its acquisition of a majority stake in another French drug manufacturer, Laboratoires Debat (Marketletter February 15).
Fournier says that Labs Debat will maintain its autonomy in France, and that Debat's current products and those in development will also be handled by Fournier's foreign subsidiaries, six of which are within the European Community, three in continental Europe and one in Canada. In France, Debat will benefit from promotion and sales efforts of Fournier's subsidiaries Humex and Urgo (Marketletter February 1).
The five research centers at Chenove, Daix, Garches, Sulzbach and Vicq will become the responsibility of Fournier. The R&D team consists of 470 researchers and technicians, and the R&D budget for 1993 amounts to over 400 million French francs ($71.4 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze